Joseph Schwartz
Stock Analyst at Leerink Partners
(3.22)
# 972
Out of 4,901 analysts
139
Total ratings
33.85%
Success rate
18.57%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Schwartz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KALV KalVista Pharmaceuticals | Maintains: Outperform | $18 → $20 | $15.17 | +31.84% | 6 | Jul 7, 2025 | |
| INSM Insmed | Maintains: Outperform | $100 → $115 | $102.87 | +11.79% | 4 | Jun 10, 2025 | |
| FULC Fulcrum Therapeutics | Upgrades: Outperform | $4 → $12 | $7.86 | +52.67% | 4 | May 23, 2025 | |
| MAZE Maze Therapeutics | Initiates: Outperform | $28 | $16.19 | +72.95% | 1 | Feb 25, 2025 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $20 → $40 | $16.40 | +143.98% | 6 | Oct 11, 2024 | |
| APLT Applied Therapeutics | Maintains: Outperform | $11 → $14 | $0.42 | +3,212.04% | 2 | Sep 19, 2024 | |
| ANTX AN2 Therapeutics | Upgrades: Outperform | n/a | $1.05 | - | 3 | Jul 3, 2024 | |
| SLDB Solid Biosciences | Upgrades: Outperform | $12 | $5.39 | +122.63% | 6 | Jun 24, 2024 | |
| MREO Mereo BioPharma Group | Maintains: Outperform | $6 → $8 | $1.71 | +367.84% | 2 | Jun 20, 2024 | |
| SYBX Synlogic | Downgrades: Market Perform | $1 | $1.32 | -24.24% | 4 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $6 | $3.93 | +52.67% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $48 | $47.75 | +0.52% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $22.99 | -21.71% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $33 → $34 | $42.00 | -19.05% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $122 → $130 | $56.62 | +129.60% | 10 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $160 | $18.21 | +778.64% | 13 | Jan 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $148 → $163 | $174.75 | -6.72% | 15 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $1.45 | +589.66% | 7 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $33 | $1.24 | +2,561.29% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $12 | $8.99 | +33.48% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $115 → $108 | $27.20 | +297.06% | 6 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $39 | $31.83 | +22.53% | 1 | May 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $4 | $0.81 | +391.40% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $30 | $13.38 | +124.22% | 2 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $50 | $31.70 | +57.73% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $30 | $55.32 | -45.77% | 6 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $56 | $13.96 | +301.15% | 1 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $5.91 | +136.89% | 12 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $12 | $2.38 | +405.26% | 2 | Sep 26, 2017 |
KalVista Pharmaceuticals
Jul 7, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $15.17
Upside: +31.84%
Insmed
Jun 10, 2025
Maintains: Outperform
Price Target: $100 → $115
Current: $102.87
Upside: +11.79%
Fulcrum Therapeutics
May 23, 2025
Upgrades: Outperform
Price Target: $4 → $12
Current: $7.86
Upside: +52.67%
Maze Therapeutics
Feb 25, 2025
Initiates: Outperform
Price Target: $28
Current: $16.19
Upside: +72.95%
Travere Therapeutics
Oct 11, 2024
Maintains: Outperform
Price Target: $20 → $40
Current: $16.40
Upside: +143.98%
Applied Therapeutics
Sep 19, 2024
Maintains: Outperform
Price Target: $11 → $14
Current: $0.42
Upside: +3,212.04%
AN2 Therapeutics
Jul 3, 2024
Upgrades: Outperform
Price Target: n/a
Current: $1.05
Upside: -
Solid Biosciences
Jun 24, 2024
Upgrades: Outperform
Price Target: $12
Current: $5.39
Upside: +122.63%
Mereo BioPharma Group
Jun 20, 2024
Maintains: Outperform
Price Target: $6 → $8
Current: $1.71
Upside: +367.84%
Synlogic
Feb 9, 2024
Downgrades: Market Perform
Price Target: $1
Current: $1.32
Upside: -24.24%
Aug 15, 2023
Downgrades: Market Perform
Price Target: $6
Current: $3.93
Upside: +52.67%
Mar 17, 2023
Initiates: Market Perform
Price Target: $48
Current: $47.75
Upside: +0.52%
Feb 3, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $22.99
Upside: -21.71%
Feb 3, 2023
Maintains: Market Perform
Price Target: $33 → $34
Current: $42.00
Upside: -19.05%
Feb 3, 2023
Maintains: Outperform
Price Target: $122 → $130
Current: $56.62
Upside: +129.60%
Jan 20, 2023
Reiterates: Outperform
Price Target: $160
Current: $18.21
Upside: +778.64%
Jan 17, 2023
Maintains: Outperform
Price Target: $148 → $163
Current: $174.75
Upside: -6.72%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $1.45
Upside: +589.66%
Nov 10, 2022
Maintains: Outperform
Price Target: $40 → $33
Current: $1.24
Upside: +2,561.29%
Nov 4, 2022
Maintains: Outperform
Price Target: $17 → $12
Current: $8.99
Upside: +33.48%
Nov 3, 2022
Maintains: Outperform
Price Target: $115 → $108
Current: $27.20
Upside: +297.06%
May 26, 2022
Maintains: Outperform
Price Target: $36 → $39
Current: $31.83
Upside: +22.53%
May 12, 2022
Maintains: Outperform
Price Target: $6 → $4
Current: $0.81
Upside: +391.40%
May 12, 2022
Maintains: Outperform
Price Target: $34 → $30
Current: $13.38
Upside: +124.22%
May 11, 2022
Maintains: Outperform
Price Target: $53 → $50
Current: $31.70
Upside: +57.73%
May 5, 2022
Maintains: Outperform
Price Target: $50 → $30
Current: $55.32
Upside: -45.77%
May 3, 2022
Maintains: Outperform
Price Target: $71 → $56
Current: $13.96
Upside: +301.15%
Feb 24, 2022
Maintains: Outperform
Price Target: $16 → $14
Current: $5.91
Upside: +136.89%
Sep 26, 2017
Maintains: Outperform
Price Target: $10 → $12
Current: $2.38
Upside: +405.26%